Pharmaceutical News and Articles

FDA Approves Zevaskyn for Rare, Genetic Skin Disorder

The U.S. Food and Drug Administration has approved Zevaskyn (prademagene zamikeracel) for patients with the rare, genetic skin disorder recessive dystrophic epi

Lifestyle Poses Greatest Risk For Cardiac Arrest

Nearly two-thirds of cardiac arrest cases could be prevented by managing lifestyle, environmental and personal health risks, a new study says. Researchers found

Sitting Too Long Each Day May Lead to Neck Pain, Study Finds

TUESDAY, April 29, 2025 If you spend hours a day glued to your phone or seated at a desk, you re setting yourself up for serious neck pain, a recent study warns

Food Companies Race to Replace Artificial Colors With Natural Alternatives

TUESDAY, April 29, 2025 The push to remove artificial colors from U.S. foods is gaining speed, but making the change won t be easy or quick. Last week, U.S. hea

Hydroxyurea Has Sustained Clinical Benefits in Children With Sickle Cell Anemia

For children with sickle cell anemia (SCA), hydroxyurea has sustained clinical benefits in terms of reducing emergency department visits and hospital days, acco

AACR: Pretrained Machine Learning Models Help Diagnose Nonmelanoma Skin Cancer

Leveraging whole slide embedding from pretrained foundation models (FMs) improves nonmelanoma skin cancer (NMSC) diagnosis, according to a study presented at th

2019 to 2023 Saw Increase in Prevalence of Psilocybin Use in the United States

The prevalence of lifetime and past-year use of psilocybin increased from 2019 to 2023 among all age groups in the United States, according to a study published

AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors

A neoadjuvant programmed cell death 1 (PD-1) blockade enables nonoperative management among patients with early-stage mismatch repair-deficient (dMMR) solid tum

AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer

Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented at the a

FDA Approves Zevaskyn (prademagene zamikeracel) Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa